Resorbable implants to treat pectus excavatum and silicone breast implant revision / congenital defect correction First patients treated in Australia BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced the start of two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary […]
continue readingBellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella
Successful initial treatment of pectus excavatum patient in Australia Data published in the European Journal of Plastic Surgery confirms Bellaseno’s novel approach in soft tissue engineering BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella® in the European […]
continue readingBellaSeno Appoints Tobias Grossner to Chief Medical Officer
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the appointment of Dr. med. Tobias Grossner as Chief Medical Officer (CMO). Dr. Grossner brings strong clinical expertise in trauma surgery and regenerative medicine and has previously been working with BellaSeno as an independent consultant. In addition, Dr. Grossner […]
continue readingBellaSeno Receives Australian Public Grant Totaling AUD 1 Million
Winner of the Australian Global Innovation Linkages Program Funding dedicated to advancing regenerative scaffolds for breast reconstruction and large bone defects BellaSeno to lead consortium of renowned commercial and academic partners BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that its Australian subsidiary BellaSeno Pty Ltd has […]
continue readingBellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regeneration
. Collaboration with Fraunhofer IZI further expanded Funding provided by Sächsische Aufbaubank BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in […]
continue readingBellaSeno Wins Prestigious German Innovation Award 2021
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business – Medical Technologies. BellaSeno has been chosen among about 700 applicants from 30 […]
continue readingBellaSeno and Fraunhofer Institute for Production Technology IPT Receive EUR 1.4 Million BMBF Grant
Funding dedicated to the development of commercial-scale, fully automated additive manufacturing of resorbable medical implants First-ever industrial-scale, additive manufacturing platform of medical implants BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, and the Fraunhofer Institute for Production Technology IPT today announced that both parties have received a grant totaling […]
continue readingBellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facility for Resorbable Medical Implants
. – Seamless transition from R&D to commercial-scale additive manufacturing – Leading-edge cleanroom, no-touch manufacturing – GMP capabilities for internal and contract manufacturing BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer […]
continue readingBellaSeno Announces First-In-Human Trial of its Novel, Absorbable Soft Tissue Reconstruction Scaffold and Granting of Key U.S. Patent
First patient with Pectus Excavatum congenital defect has undergone surgery in Australia Minimally invasive procedure and fully absorbable scaffold expected to provide for improved safety and recovery Key U.S. patent granted for the design and porosity of Senella® platform BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced […]
continue reading